JP6749171B2 - Inhalation gas efficacy verification method - Google Patents

Description

The disclosed embodiments relate to a method for verifying the efficacy of inhaled gas.

It has hitherto been considered that taking hydrogen into the human body is effective in removing active oxygen species which are considered to cause lesions and functional disorders. Therefore, a hydrogen gas generation device has been proposed that generates hydrogen gas from saturated vapor and can take the hydrogen gas into the human body as an inhaled gas (for example, see Patent Document 1).

In addition, in recent years, for example, for a vapor mixed gas containing hydrogen gas, it is expected to enhance the immunity of the living body and to suppress the onset of arteriosclerosis and acute myocardial infarction, and its verification has been performed. There is.

At the time of verification, we examine how the dynamics of in vivo biomarkers change before and after inhalation of inhaled gas.In such an inspection, it is common to use serum that is separated and collected from blood collected from the subject. It was target.

International Publication No. 2015/045118

However, blood sampling needs to be performed in a prescribed medical facility under the guidance of a doctor and the like, so that it takes a lot of time and labor to verify the effect of inhaled gas on the human body.

One aspect of the embodiment is made in view of the above, and an object thereof is to provide a method for verifying the effect of inhaled gas, which can easily verify the effect of inhaled gas on the human body.

(1) A method for verifying the efficacy of inhaled gas according to an aspect of the embodiment is a method for verifying the efficacy of inhaled gas on the human body by analyzing the dynamics of biomarkers, which comprises a primary saliva collecting step, It has a secondary saliva collection step, a concentration inspection step, and a determination step. The primary saliva collecting step collects saliva of the subject before inhaling the inhaled gas, and the secondary saliva collecting step collects saliva of the subject after inhaling the inhaled gas. The concentration testing step tests the concentration of interleukin-1β in each saliva collected in the primary saliva collecting step and the secondary saliva collecting step. In the determination step, the first interleukin 1β concentration in the saliva collected in the primary saliva collecting step is compared with the second interleukin 1β concentration in the saliva collected in the secondary saliva collecting step. Based on this, the activation of the immune system by the inhaled gas is judged. Then, the secondary saliva collecting step includes an early saliva collecting step that is executed within 30 minutes at the latest after the subject inhales the inhaled gas.

(2) Further, in the method for verifying the efficacy of inhaled gas according to one aspect of the embodiment, in the above (1), the step of collecting the early saliva is 10 to 20 minutes after the subject inhales the inhaled gas. It is characterized by being executed in between.

(3) Further, in the method for verifying the efficacy of inhaled gas according to one aspect of the embodiment, in the above (1) or (2), the inhaled gas further heats superheated steam generated by heating raw water. It is a vapor mixed gas containing the produced hydrogen gas, and the concentration of the hydrogen gas contained in the vapor mixed gas is less than 4.2 Vol %.

(4) Further, the method for verifying the efficacy of inhalation gas according to one aspect of the embodiment is characterized in that in the above (3), the concentration of the hydrogen gas is 0.1 to 0.3 Vol %.

(5) In addition, the method for verifying the efficacy of inhaled gas according to an aspect of the embodiment is the method according to any one of (1) to (4) above, wherein in the concentration test step, the enzyme antibody method is used to perform the interactivity test. Characterized by testing the concentration of leukin-1β.

According to one aspect of the embodiment, it is possible to easily verify the effect of hydrogen gas or inhaled gas containing hydrogen gas on the human body without performing blood collection or the like under strict regulations.

FIG. 1 is an explanatory diagram showing a procedure of an inhalation gas efficacy verification method according to an embodiment. FIG. 2 is an explanatory diagram showing a usage state of the hydrogen gas generator used in the above-described inhalation gas efficacy verification method. FIG. 3 is an explanatory diagram showing a configuration example of the above hydrogen gas generator. FIG. 4 is an explanatory diagram showing the effect of inhaled gas on interleukin-1β in saliva and the expected efficacy in the embodiment.

Hereinafter, the inhalation gas efficacy verification method disclosed in the present application will be described in detail through embodiments. The present invention is not limited to the embodiments described below.

FIG. 1 is an explanatory diagram showing a procedure of an inhalation gas efficacy verification method according to an embodiment. FIG. 2 is an explanatory diagram showing a usage state of the hydrogen gas generator 10 used in the above-described inhalation gas efficacy verification method, and FIG. 3 is an explanatory diagram showing one configuration example of the hydrogen gas generator 10 above. Further, FIG. 4 is an explanatory diagram showing the influence of inhaled gas on interleukin-1β in saliva and the expected efficacy in the embodiment.

By the way, the intake gas in the present embodiment refers to a vapor mixed gas containing hydrogen gas generated by further heating superheated steam generated by heating raw water. The concentration of hydrogen gas contained in the vapor mixed gas is less than 4.2 Vol%, and more specifically, the concentration of hydrogen gas is 0.1 to 0.3 Vol%.

Such a vapor mixed gas can be generated by the hydrogen generator 10 shown in FIGS. 2 and 3.

That is, the hydrogen gas generator 10 generates a vapor mixed gas containing hydrogen gas (H ₂ ), makes it into an appropriate concentration and can take it into the human body, and as shown in FIG. The user D including the subject can attach the tip of the gas inhalation pipe 14 extending from the casing 11 to the nose or mouth to inhale the vapor mixed gas containing the generated hydrogen gas at an appropriate concentration. ..

Further, a door 13 covering the front inspection port is openably and closably attached to one side peripheral wall of the casing 11 formed in a rectangular box shape, and a caster 12 is attached to a bottom portion thereof.

Further, as shown in FIG. 3, a water supply unit 2, a superheated steam heating unit 3, a gas extraction unit 5, and a cooling unit 6 are provided inside the casing 11. Then, while the raw water supplied from the water supply unit 2 is heated by the superheated steam heating unit 3 to generate steam, the steam is further heated to generate superheated steam, and the steam mixed gas containing hydrogen gas is further heated. Can be generated.

Next, gas-liquid separation is performed from the mixed fluid containing the vapor mixed gas and superheated steam, and the separated vapor mixed gas is cooled to a temperature at which it can be sucked into the human body by the cooling unit 6 and taken out from the gas extraction unit 5 to obtain the vapor mixed gas. The hydrogen gas contained in can be inhaled.

As shown in FIG. 3, the water supply unit 2 includes a water supply tank 21 that stores raw water and an adjustment tank 22 that adjusts the liquid level of the raw water supplied to the superheated steam heating unit 3. A level switch (not shown) for detecting the amount of raw water is arranged in the water supply tank 21, and a water supply level meter (not shown) is provided in the adjustment tank 22.

The water supply tank 21 and the adjustment tank 22 are connected by a water supply pipe 40 via an electromagnetic valve 23. The opening/closing operation of the solenoid valve 23 is controlled by a control unit (not shown) provided in the casing 11 according to the value of the water level meter.

The superheated steam heating unit 3 includes, as a heating device, a heating pipe 31 into which raw water from the adjustment tank 22 flows, and a coil heater 7 that winds around the heating pipe 31 over substantially the entire length thereof. That is, the superheated steam heating unit 3 heats the raw water supplied from the water supply unit 2 to the heating pipe 31 via the communication pipe 50 by the coil heater 7 to generate superheated steam, and the superheated steam is further heated to 600° C. to 700° C. The mixture is heated to 0° C. to generate a vapor mixed gas containing hydrogen gas (H ₂ ) of about 1.2 to 2.3%. The circumference of the coil heater 7 is covered with a heat insulating material 32 having a predetermined thickness.

The amount of raw water supplied to the heating pipe 31 is kept constant by the adjustment tank 22. That is, the liquid level in the adjustment tank 22 and the liquid level in the heating pipe 31 are at the same level. The space above the liquid level in the heating pipe 31 is a space in which steam is generated, and the steam in the space is further heated to become superheated steam. Even so, a vapor mixed gas containing a low concentration (for example, 1.2 to 2.3%) of hydrogen gas (H ₂ ) is generated. Therefore, inside the heating pipe 31, the steam mixed gas and the superheated steam are mixed in a high temperature state.

As shown in FIG. 3, the gas extraction unit 5 includes a heat radiation pipe 80, a gas delivery case 8, and a gas suction pipe 14. That is, the gas delivery case 8 is connected to the other end of the heat radiation pipe 80, one end of which communicates with the upper portion of the heating pipe 31, and the gas suction pipe 14 communicates with the gas delivery case 8.

An air supply fan (not shown) is housed in the gas delivery case 8. By the operation of the air supply fan, the vapor mixed gas containing hydrogen gas is smoothly sent out of the system through the gas suction pipe 14 (for example, a cannula).

By the way, the radiating pipe 80 forming a part of the gas extraction part 5 is formed in a coil shape to facilitate heat dissipation, and forms a part of the cooling part 6. That is, it can be said that the cooling unit 6 is included in the gas extraction unit 5. The cooling unit 6 includes a radiating pipe 80 and a cooling fan 62 that is arranged so as to blow air toward the radiating pipe 80.

With the configuration described above, the raw water supplied from the water supply tank 21 to the heating pipe 31 of the superheated steam heating unit 3 is heated by the coil heater 7 and boils into steam. Then, the steam is further heated by the coil heater 7 to become superheated steam, and when the temperature reaches 600° C. to 700° C. under atmospheric pressure, the steam containing hydrogen gas separated from oxygen, though having a low concentration, is included. A mixed gas is produced.

Thus, the vapor mixed gas containing hydrogen gas can be supplied to the human body through the gas suction pipe 14 (see FIG. 2). When the present hydrogen gas generator 10 is used, not only hydrogen gas but also oxygen gas is taken into the human body, but the concentration of hydrogen gas contained in the vapor mixed gas is less than 4.2 Vol %. Further, since the vapor mixed gas is sufficiently cooled by the cooling unit 6 (for example, about 20 to 25° C.), it can be sucked easily and safely.

The inhalation gas according to the present embodiment, which is generated by the hydrogen generator 10 described above, that is, the vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol%, activates the bioimmunity function to the human body. It is believed to work.

By the way, interleukin-1β (hereinafter referred to as “IL-1β”) is one of cytokines involved in immune reaction, that is, one of proteins secreted from cells of the immune system.

IL-1β is a glycoprotein mainly produced by the largest monocyte among leukocytes and macrophages (also called histiocytes) that differentiate from such monocytes, and has a molecular weight of about 17 KDa (Dalton).

Induction of immune response by such IL-1β is an important function in activation of innate immune system. On the other hand, IL-1β is known to have an adjuvant effect of enhancing immunogenicity (immunogenicity) even in the adaptive immune system.

In addition, the physiological activities of IL-1β are extremely diverse, and serve as T cells that are the center of adaptive immunity, B cells that are antibody-producing cells that occupy 20 to 30% of lymphocytes, and act as major factors of innate immunity. It is known to activate NK cells, which are a type of cytotoxic lymphocytes, and further vascular endothelial cells that control adhesion and passage of leukocytes.

In addition to IL-1β, which is a kind of white blood cells, promotes the expression of adhesion molecules responsible for cell adhesion and neutrophil increase, IL-1 to IL-8, and a tumor necrosis factor (TNF: Tumor Necrosis) which is a kind of cytokine. Factors, interferons (IFNs), and induction of colony stimulating factor (CSF), which has an action of stimulating leukocyte stem cells other than lymphocytes to promote growth, are known.

Furthermore, IL-1β is also known to induce nitric oxide (N0) production from macrophages, which are a type of white blood cells. Nitric oxide is produced by vascular endothelial cells and regulates vascular endothelial function.

In particular, the most important function of IL-1β in the immune system is the induction of interleukin 2 (hereinafter referred to as “IL-2”) production from helper T cells that help B cells to differentiate into antibody-producing cells. Furthermore, it is said to promote the differentiation/proliferation of T cells through such IL-2 to activate the biological defense ability, particularly the infection defense ability.

Thus, IL-1β has an important function in activation of the innate immune system, and by analyzing the dynamics of IL-1β as a biomarker, for example, the hydrogen generator 10 described above can be used. It is believed possible to verify the efficacy of the inhaled gas produced (see FIGS. 2 and 3). Here, the biomarker refers to a substance such as a protein that reflects the presence or progress of a predetermined disease according to its concentration.

Therefore, it was decided to verify the effect of the inhaled gas, which is a vapor mixed gas containing hydrogen gas at a concentration of 0.1 to 0.3 Vol%, on the human body.

The method for verifying the effect of inhaled gas according to the present embodiment is a method for verifying the effect of inhaled gas containing hydrogen gas on the human body by analyzing the dynamics of IL-1β as a biomarker, As shown in FIG. 1, it has a primary saliva collection step S11, an inhalation step S12, a secondary saliva collection step S13, a concentration inspection step S14, and a determination step S15.

That is, as the primary saliva collecting step S11, first, the saliva of the subject before the inhalation gas is inhaled is collected.

Next, in the suction step S12, the hydrogen generator 10 (see FIGS. 2 and 3) is used to suck the suction gas generated in the hydrogen generator 10. Here, the subject was allowed to inhale for 60 minutes.

Next, as a secondary saliva collecting step S13, after inhaling an inhaled gas which is a vapor mixed gas containing hydrogen gas, saliva is collected from a subject every predetermined time. In this secondary saliva collecting step, after inhaling inhaled gas, an early saliva collecting step S131 that collects saliva after 15 minutes, a mid-term saliva collecting step S132 that collects saliva after 30 minutes, and saliva after 60 minutes The latter stage saliva collecting step S133 of collecting is included.

The early saliva collecting step S131 of the secondary saliva collecting step S13 is supposed to be executed within 30 minutes at the latest after the subject inhales the inhalation gas. Here, the process was performed 15 minutes after the gas was inhaled.

Then, as the concentration inspection step S14, the concentration of IL-1β in the saliva collected in each of the steps S131, S132, and S133 in the secondary saliva collection step S13 is tested. Here, the inspection of the concentration of IL-1β in the concentration inspection step S14 is performed by using the enzyme antibody method (EIA method: Enzyme Immunoassay).

Furthermore, as the determination step S15, the activation of the immune function in the inhaled gas is confirmed from the test results of the concentration of IL-1β in saliva collected in the early saliva collecting step S131, the middle saliva collecting step S132, and the late saliva collecting step S133. judge.

In the present embodiment, the above method was used to verify the efficacy of inhaled gas for 9 subjects. Table 1 shows the inspection result in the concentration inspection step S14 according to the present embodiment.

As is clear from Table 1, when inhaling an inhaled gas which is a vapor mixed gas containing hydrogen gas at a concentration of 0.1 to 0.3 Vol%, the concentration of IL-1β increases evenly after inhaling the gas. .. Moreover, it was found that the concentration of IL-1β increased in all subjects 15 minutes after inhalation. In addition, in the table, a mark "-" in a square indicates that a complete test could not be performed and the concentration of IL-1β was not detected.

The p-value indicating that the concentration of IL-1β after inhaling the inhaled gas was significantly increased compared to that before inhalation was 0.0018 (p<0.01) 15 minutes after inhalation. After 30 minutes, it was 0.012 (p<0.05).

As described above, an increase in the concentration of IL-1β means activation of the innate immune system as well as the adaptive immune system. Therefore, when a vapor mixed gas containing hydrogen gas with a concentration of 0.1 to 0.3 Vol% is inhaled, it is considered that the activation action of the biological immune function is caused.

That is, as shown in FIG. 4, as a suction gas according to the present embodiment, a vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol%, which is generated by the hydrogen generator 10, is suctioned. In this case, it is considered that the concentration of IL-1β in saliva is increased and a proper local immune response is induced.

As a result, it is considered that activation of the bioimmunity function occurs, and induction of regulation of the bioimmunity function, enhancement of infection protection immunity, and enhancement of cancer (tumor) immunity are expected.

Moreover, in the method for verifying the efficacy of inhaled gas according to the present embodiment, instead of using blood collected from a subject, saliva collected from the subject is used, and IL-1β in the saliva is used as a biomarker for the concentration of IL-1β. I try to analyze the dynamics. Therefore, a significant change in the concentration was confirmed even just 15 minutes after the inhalation gas was inhaled. Therefore, the effect of inhaled gas on the human body can be verified very easily as compared with the case where blood collection is performed at a predetermined medical facility under the guidance of a doctor or the like.

Here, in order to confirm the superiority of using IL-1β as a biomarker, another biomarker was used as a comparative example, and the efficacy of inhaled gas was verified for 7 subjects.

Table 2 shows the results of examining the concentration of sCD44 in saliva instead of IL-1β as a comparative example in the method for verifying the efficacy of inhaled gas.

The sCD44 used as a comparative example will be briefly described below.

CD44 has many isoforms and is widely distributed in living cells such as leukocytes, erythrocytes, epithelial cells and fibroblasts. CD44 is also expressed on tissue macrophages, fibroblasts, etc. in addition to hematopoietic cells such as lymphocytes and granulocytes.

CD44 is a type IV collagen also called membrane type collagen, a giant glycoprotein, fibronectin, which is a cell adhesion molecule, and a standard type (CD44v) whose basic function is adhesion to hyaluronic acid, epithelial cells, macrophages, leukemia cells. , Epithelial type (CD44E) which is highly expressed in vascular endothelial cells, particularly endothelial cells in inflammatory sites and lymph nodes, and soluble type (sCD44) found in serum/plasma and joint synovial fluid.

Among the above, sCD44, which is soluble CD44 in particular, may show extremely high levels in synovial fluid of patients with rheumatoid arthritis in the active phase and serum of patients with malignant tumors, and thus the intensity of inflammation, disease activity, and tumor malignancy. -Correlates with metastasis. The dynamic analysis of sCD44 in circulating blood or tissue fluid is said to be a biomarker for inflammatory response and disease activity of inflammatory pathological conditions.

Also in the comparative example, first, saliva of a subject before inhaling the inhaled gas is collected, and then the inhaled gas generated by the hydrogen generator 10 (see FIGS. 2 and 3) is inhaled, and then for 15 minutes. After 30 minutes and 60 minutes, saliva is collected. Then, here, the concentration of sCD44 in the collected saliva was examined by the original construction enzyme antibody method.

As shown in Table 2, in this example, there is no significant change in the concentration of sCD44 in saliva before and after gas inhalation. The p-value in this case was 0.1169 after 15 minutes of inhalation and 0.2315 after 30 minutes of inhalation, so there is no significance in the change in the concentration of sCD44 before and after inhaling the suction gas. Not accepted.

Thus, it can be seen that the vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol% does not particularly affect the dynamics of sCD44 in saliva even if the gas is inhaled.

As another comparative example, the efficacy of inhaled gas was verified in 9 subjects using a specific IgA antibody as a biomarker.

Table 3 shows, as another comparative example, the results of examining the concentration of a specific IgA antibody (hereinafter referred to as “BG-IgA”) in saliva in the method for verifying the efficacy of inhaled gas.

BG-IgA used as a comparative example will be briefly described below.

Humans and animals have an immune system that protects the body from the outside. In particular, "mucosal immunity" exists in the mucous membrane, which is the entrance of many microorganisms such as viruses and bacteria, and the antigen-specific secretory IgA antibody is induced.

The mucosal tissue-induced IgA antibody-producing cells can also home to another mucosal tissue by the common mucosal immune system (CMIS). In particular, the lactogenic IgA antibody-producing cells are induced in intestinal tract-related lymphoid tissue, nasopharyngeal-related lymphoid tissue, bronchial-related lymphoid tissue, and the like, and then intestinal mucosa lamina propria, respiratory mucosa lamina propria, mammary gland, lacrimal gland, salivary gland, urine It homes to the genitals and activates a biological defense function.

The kinetic analysis of β-glucan (BG)-specific IgA antibody (BG-IgA), which is a fungal-derived cell wall constituent, is considered to provide important information for grasping and considering the mucosal immune mechanism of the living body. In particular, BG-IgA in saliva is said to exert its power as a defense against infection against influenza virus and the like.

Also in this comparative example, first, the saliva of the subject before inhaling the inhaled gas is collected, and then the inhaled gas generated by the hydrogen generator 10 (see FIGS. 2 and 3) is inhaled. After that, saliva was collected after 15 minutes, 30 minutes, and 60 minutes, and the concentration of the fungal cell wall β-glucan (BG)-specific IgA antibody (BG-IgA) in the collected saliva was measured by the original construction enzyme antibody method. Inspected.

As shown in Table 3, also in this example, no significant change was observed in the concentration of BG-IgA in saliva before and after inhaling the gas. In this case, the p value is 0.815 after 15 minutes of inhalation and 0.745 after 30 minutes of inhalation. It is recognized that the change in the concentration of BG-IgA has no significance. In addition, since the p value was 0.026<0.05 after 60 minutes of inhalation, it was confirmed that the concentration of BG-IgA was significantly increased when inhaled for a long time.

From the above-mentioned verification results of the effect of the inhaled gas on the human body, among the plurality of biomarkers that can be collected from saliva, if it is IL-1β, the kinetics of the concentration is short (for example, 10 to 20 minutes after gas inhalation) It turns out that it increases significantly.

Therefore, if the method for verifying the efficacy of inhaled gas according to the present embodiment, only saliva of a subject is collected without using blood that needs to be taken in a predetermined medical facility under the guidance of a doctor when collecting blood. Moreover, since the saliva can be collected at about 15 minutes after the gas is inhaled, the effect of hydrogen gas or inhaled gas containing hydrogen gas on the human body can be easily verified.

Since the timing of collecting saliva can be set to a short time of about 15 minutes after gas inhalation, for example, the hydrogen generator 10 (which can generate a vapor mixed gas containing hydrogen gas with a concentration of 0.1 to 0.3 Vol%). A user who plans to purchase (see FIG. 2 and FIG. 3) or the like, when trying the hydrogen generator 10 (so-called “trial use”), sees its effect in a short period of time and changes in biomarker dynamics. You can check it at.

Further, from the manufacturing side of the hydrogen gas generator 10, a vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol% is effective in improving immunity even if inhaled for a short time. It becomes possible to sing.

As described above, the concentration of IL-1β, sCD44 and BG-IgA in saliva was examined as a biomarker after inhaling a vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol%. As a result, a significant increase in the IL-1β concentration in saliva was observed 15 minutes after gas inhalation. On the other hand, in sCD44 and BG-IgA in saliva, no significant change was observed in such a short time (for example, 15 minutes), and the finding was a specific kinetic of IL-1β.

In this way, by inhaling the vapor mixed gas containing hydrogen gas having a concentration of 0.1 to 0.3 Vol% generated by the hydrogen gas generator 10, the concentration of IL-1β is specifically short (10 It was found to increase within 20 minutes). This indicates that the vapor mixed gas containing hydrogen gas at a concentration of 0.1 to 0.3 Vol% activates the biological immunity enhancing action in a short time and induces the biological protection function. Therefore, it is considered that such results and the above-described method for verifying the effect of inhaled gas have great promise for clinical application.

From the above-described embodiment, the following inhalation gas efficacy verification method is realized.

(1) A method for verifying the effect of inhaled gas on a human body by analyzing the dynamics of biomarkers, which is a primary saliva sampling method for collecting saliva of a subject before inhaling inhaled gas. Step S11, a secondary saliva collection step S13 that collects saliva of the subject after inhaling inhaled gas, and interleukin-1β in each saliva collected in the primary saliva collection step S11 and the secondary saliva collection step S13. A concentration test step S14 for testing the concentration, a first interleukin 1β concentration in the saliva collected in the primary saliva collecting step S11, and a second interleukin 1β concentration in the saliva collected in the secondary saliva collecting step S13 are compared, And a determination step S15 for determining activation of the immune system by the inhaled gas based on the comparison result, and the secondary saliva collecting step S13 is performed within 30 minutes at the latest after the subject inhales the inhaled gas. A method for verifying the efficacy of inhaled gas, which comprises a saliva collecting step S131.

(2) In the above (1), the early saliva collecting step S131 is a method for verifying the efficacy of inhaled gas, which is executed within 10 to 20 minutes after the subject inhales the inhaled gas.

(3) In the above (1) or (2), the suction gas is a vapor mixed gas containing hydrogen gas produced by further heating superheated steam generated by heating raw water, and is included in the vapor mixed gas. The method for verifying the efficacy of inhaled gas in which the concentration of hydrogen gas is less than 4.2 Vol%.

(4) The method for verifying the efficacy of inhaled gas according to (3) above, wherein the concentration of hydrogen gas is 0.1 to 0.3 Vol%.

(5) In the above-mentioned (1) to (4), in the concentration inspection step S14, an inhalation gas efficacy verification method for inspecting the concentration of interleukin-1β using an enzyme antibody method.

Further effects and modifications of the above-described embodiment can be easily derived by those skilled in the art. As such, the broader aspects of the present invention are not limited to the specific details and representative embodiments shown and described above. Accordingly, various modifications may be made without departing from the spirit or scope of the general inventive concept defined by the appended claims and their equivalents.

S11 Primary saliva collection step S13 Secondary saliva collection step S14 Concentration inspection step S15 Judgment step 10 Hydrogen gas generator

Claims (5)

A method for verifying the effect of inhaled gas on a human body by analyzing the dynamics of biological biomarkers.
A primary saliva collecting step of collecting saliva of the subject before inhaling the inhaled gas,
A secondary saliva collecting step of collecting saliva of the subject after inhaling the inhaled gas,
A concentration testing step for testing the concentration of interleukin-1β in each saliva collected in the primary saliva collecting step and the secondary saliva collecting step;
The first interleukin 1β concentration in the saliva collected in the primary saliva collecting step is compared with the second interleukin 1β concentration in the saliva collected in the secondary saliva collecting step, and immunization by inhalation gas is performed based on the comparison result. A determination step for determining activation of Noh;
Have
The secondary saliva collecting step includes an early saliva collecting step that is performed within 30 minutes at the latest after the subject inhales the inhaled gas. The method for verifying the efficacy of inhaled gas according to claim 1, wherein the early saliva collecting step is executed within 10 to 20 minutes after the subject inhales the inhaled gas. The inhaled gas is
It is a vapor mixed gas containing hydrogen gas produced by further heating superheated steam generated by heating raw water, and the concentration of the hydrogen gas contained in the vapor mixed gas is less than 4.2 Vol%. The efficacy verification method of the inhalation gas according to claim 1 or 2. The inhalation gas efficacy verification method according to claim 3, wherein the concentration of the hydrogen gas is 0.1 to 0.3 Vol%. The method for verifying the efficacy of inhaled gas according to any one of claims 1 to 4, wherein in the concentration testing step, the concentration of the interleukin-1β is tested using an enzyme antibody method.

Images